Shield Therapeutics is a specialty pharmaceutical company focused on the development and commercialisation of late‑stage, hospital‑focused pharmaceuticals which address areas of unmet medical need.
Find out moreOur lead product is approved for the treatment of iron deficiency with or without anaemia in adults in the European Union, the United States and Switzerland and has exclusive IP rights until the mid-2030s. In Europe it is marketed as
Feraccru® with commercialisation led by Norgine BV and in the USA the product which benefits from NCE exclusivity until 2024 will be marketed as Accrufer™.
We are looking forward to attending the @LSXLeaders #LifestarAwards this evening. #STX is a finalist in the Biotec… https://t.co/vAe2AeNxE8
A great opportunity for #STX team to update investors. Thank you @WalbrookPR for organising. https://t.co/BT4HizVXDV
RT @BioPartner: Come see the UK delegation @BIOEurope and see who's attending from the UK at https://t.co/oHaN8wjIXn @nanomerics @OBN_UK…
